Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiol Therapeutics (CRDL), Neurocrine (NBIX) and I...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol ...

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiol Therapeutics (CRDL), Annexon Biosciences (AN...

Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Annexon Biosciences (ANNX) and VolitionRX (VNRX)

The latest update is out from Cardiol Therapeutics ( ($TSE:CRDL) ). In its year-end 2025 operational update released on April 1, 2026, Cardiol Ther...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRDL	$1.30	-7.01%	496.10K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRDL	$1.30	-7.0%	496.10K
3
4
5
6

CRDL

CRDL

Get Cardiol Therapeutics Inc. Data in Excel

Get Cardiol Therapeutics Inc. Data in Excel